uniQure NVMEX:QUREN 29 Gross Margin % is 93.85% as of Mar. 2026, which is 5% above its 10-year median of 89.53. GuruFocus rates MEX:QUREN with a GF Score™ of 29/100 and a GF Value™ of MXN99.43 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 737 Biotechnology companies, uniQure NV ranks better than 84.8% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. uniQure NV's Gross Profit for the
three
months ended in Mar. 2026 was MXN60.3 Mil. uniQure NV's Revenue for the
three
months ended in Mar. 2026 was MXN64.2 Mil. Therefore, uniQure NV's Gross Margin % for the quarter that ended in Mar. 2026 was 93.85%.
The historical rank and industry rank for uniQure NV's Gross Margin % or its related term are showing as below:
MEX:QUREN'
s Gross Margin % Range Over the Past 10 Years
Min: 13.98 Med: 89.53 Max: 96.86
Current: 90.56
During the past 13 years, the highestGross Margin % of uniQure NV was 96.86%. The lowest was 13.98%. And the median was 89.53%.
MEX:QUREN's Gross Margin % is ranked better than 84.8% of 737
companies
in the Biotechnology industry
Industry Median: 60.92
vs MEX:QUREN: 90.56
uniQure NV had a gross margin of 93.85% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for uniQure NV was 0.00% per year.
uniQure NV (MEX:QUREN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
uniQure NV had a gross margin of 93.85% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
uniQure NV Gross Margin % Related Terms
uniQure NV Gross Margin % Historical Data
* Premium members only.
The historical data trend for uniQure NV's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:QUREN vs NVAX, HRMY, IOVA: Gross Margin % Comparison
For the Biotechnology subindustry, uniQure NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's Gross Margin % distribution charts can be found below:
* The bar in red indicates where uniQure NV's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
uniQure NV (MEX:QUREN) has a Gross Margin % of 93.85% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on uniQure NV and its competitors. This is near median its historical median of 89.53. Over the past decade, uniQure NV's Gross Margin % has ranged from 13.98 to 96.86. According to the industry distribution chart, uniQure NV ranks #112 out of 737 companies in the Biotechnology industry, placing it in the top 15.2%.
Is uniQure NV's Gross Margin % too high?
uniQure NV's current Gross Margin % of 93.85% is near median its 10-year median of 89.53. Over the past 10 years, this metric has ranged from a low of 13.98 to a high of 96.86. The Biotechnology industry median Gross Margin % is 60.92. uniQure NV's value of 93.85% is 54.1% above this industry median. Based on the distribution chart, uniQure NV ranks #112 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, uniQure NV has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Gross Margin % compare to NVAX and HRMY?
According to the Biotechnology industry distribution chart, uniQure NV ranks #112 out of 737 companies for Gross Margin %. This places uniQure NV in the top 15% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. uniQure NV's value of 93.85% is 54.1% above this benchmark. Historically, uniQure NV's own Gross Margin % has ranged from 13.98 to 96.86 over the past decade. While the company's 10-year median is 89.53 vs. the industry median of 60.92, uniQure NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. uniQure NV's current Gross Margin % of 93.85% is 54.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on uniQure NV and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. uniQure NV's current Gross Margin % is 93.85%, which is near median its own 10-year median of 89.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (MEX:QUREN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN99.43, compared to a current price of MXN795.45 — trading 700% above its estimated fair value. The current Gross Margin % is 93.85%, which is near median its 10-year median of 89.53 and 54.1% above the Biotechnology industry median of 60.92. uniQure NV's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For uniQure NV (MEX:QUREN), the current Gross Margin % is 93.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (MEX:QUREN) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of MXN795.45 is trading 700% above its estimated GF Value™ of MXN99.43.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for MEX:QUREN:
Gross Margin %: 93.85% (near median its 10-year median of 89.53)
GF Value™: MXN99.43 vs. price of MXN795.45 (700% above fair value)
Industry Position: 54.1% above the Biotechnology median (#112 of 737)
No single metric tells the full story. See the MEX:QUREN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
29GF Score
Get the complete analysis for MEX:QUREN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:QUREN has been successfully added to your 
